Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GRCEthis companyGrace Therapeutics, Inc.	$1.88	-9.85×	1.2×	0×	-5.37×	-60.9%	0.0%	0.0%	0.0%	-12.2%	-14.1%	-11.6%	0×	1.53×	0×	8.1×	0.0%	2	5.07	2	C+
ABVCABVC BioPharma, Inc.	$0.97	-5.46×	4.46×	0×	-7.04×	-109.1%	0.0%	0.0%	0.0%	-71.2%	-42.6%	-6.0%	0.31×	-0.38×	-17.2×	0.41×	0.0%	1	-5.28	1	C-
ATNMActinium Pharmaceuticals, Inc.	$1.60	-1.25×	5.42×	471.4×	0.12×	0.8%	100.0%	-40274.4%	-37652.2%	-432.6%	-81.4%	-58.2%	0.22×	1.4×	0×	6.2×	0.0%	4	-8.02	5	S-
CALCCalciMedica, Inc.	$1.43	-3.35×	-14,896.04×	0×	-3,521.14×	-100.0%	0.0%	0.0%	0.0%	445.1%	-209.1%	-0.0%	-1.46×	0.06×	-16.26×	3.58×	0.0%	3	-15.99	1	C-
LTRNLantern Pharma Inc.	$0.57	-1.93×	5.05×	0×	-6.26×	-1222.3%	0.0%	0.0%	0.0%	-262.0%	-21.1%	-47.5%	12.02×	-4.33×	0×	2.4×	0.0%	1	-22.94	2	C+
OKUROnKure Therapeutics, Inc.	$2.88	-0.66×	0.7×	0×	0.33×	63.3%	0.0%	0.0%	0.0%	-105.9%	-110.9%	-132.3%	0.01×	1×	0×	10.28×	0.0%	2	6.84	3	B
Peer median	—	-1.93×	4.46×	0×	-6.26×	-100.0%	0.0%	0.0%	0.0%	-105.9%	-81.4%	-47.5%	0.22×	0.06×	0×	3.58×	0.0%	2	-8.02	2	—